#Australia #Melbourne #Imaging Technology #4DMedical #CTVQ

4DMedical's CTVQ™ Receives CE Mark for European Launch

In a significant advancement, 4DMedical Limited, listed on the ASX under the code 4DX, has announced the receipt of the CE mark for its cutting-edge imaging technology, CTVQ™. This certification enables the company to introduce CTVQ™ to one of the largest global markets for respiratory imaging. This development marks a crucial step in enhancing the diagnostic capabilities of healthcare providers across the European Union.

4DMedical is at the forefront of cardiothoracic imaging software, and the CTVQ™ technology is designed to merge the anatomical precision of CT imaging with functional ventilation-perfusion mapping derived from non-contrast CT scans. By doing so, clinicians can gain quantitative insights into the regional functioning of the lungs without the need for radiotracers. This is particularly valuable in addressing pulmonary diseases that are fundamentally linked to functional anomalies in ventilation and perfusion.

The company has also announced a successful private placement, raising A$83 million to support its growth initiatives, including the expansion of CTVQ™ into European markets. CEO Andreas Fouras emphasizes the importance of this CE mark, stating that it opens access to one of the most advanced healthcare markets worldwide. With a population exceeding 450 million, and a robust imaging infrastructure, Europe is well-positioned to adopt functional lung imaging techniques, such as those offered by CTVQ™.

Currently, approximately 400,000 nuclear ventilation-perfusion scans are performed annually in the EU, highlighting a significant clinical need. CTVQ™ stands out as the first and only non-contrast ventilation-perfusion imaging technology, providing quantitative functional information about the lungs from routine CT scans without the complexities and constraints associated with traditional nuclear imaging processes.

As CTVQ™ integrates smoothly into existing hospital workflows and CT infrastructure, it alleviates the long-standing challenges associated with nuclear imaging, such as radiotracer availability and operational complexity. With this adoption, 4DMedical expects to provide advanced healthcare capabilities to numerous medical institutions, enhancing patient diagnosis, management, and treatment planning.

The growing interest in CTVQ™ is also echoed in the United States, where it is currently employed in six major university medical centers including renowned institutions like Stanford and Mayo Clinic. This early adoption in leading hospitals underscores a strong demand for the technology among radiology and pulmonary teams, and sets a roadmap for its subsequent expansion in Europe.

Given the universal nature of the clinical need addressed by CTVQ™, its introduction in Europe is anticipated to significantly impact how respiratory conditions are diagnosed and managed. 4DMedical plans to collaborate with leading hospitals and clinicians across Europe for further adoption, evaluation, and research initiatives related to CTVQ™.

In summary, 4DMedical's CTVQ™ not only introduces a novel way to visualize lung function but also represents a leap forward in respiratory healthcare, combining advanced imaging techniques with practical applications that meet significant clinical demands. As the company moves forward with its plans, the future looks promising for enhanced patient outcomes in both Europe and beyond.

For further updates and information, visit 4DMedical's official website.